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Objective: To evaluate the antitumor activity both in vitro and in vivo of saponin–
phospholipid complex of Panax notoginseng.
Methods: The in vitro cytotoxic effect of saponins extract and saponin–phospholipid
complex against human lung cancer NCI-H460 and breast cancer cell lines BT474 was
examined using MTS assay. For in vivo evaluation of antitumor potential, saponin and
saponin–phospholipid complex were administered orally in rats induced mammary
carcinogenesis by 7,12-dimethylbenz(a)anthracene, for 30 days.
Results: Our data showed that saponin–phospholipid complex had stronger anticancer
effect compared to saponin extract. The IC50 values of saponin–phospholipid complex and
saponin extract for NCI-H460 cell lines were 28.47 mg/mL and 47.97 mg/mL, respectively
and these values for BT474 cells were 53.18 mg/mL and 86.24 mg/mL, respectively. In vivo
experiments, administration of saponin, saponin–phospholipid complex and paclitaxel
(positive control) effectively suppressed 7,12-dimethylbenz(a) anthracene-induced breast
cancer evidenced by a decrease in tumor volume, the reduction of lipid peroxidation level
and increase in the body weight, and elevated the enzymatic antioxidant activities of su-
peroxide dismutase, catalase, glutathione peroxidase in rat breast tissue.
Conclusions: Our study suggests that saponin extract from Panax notoginseng and
saponin–phospholipid complex have potential to prevent cancer, especially breast cancer.1. Introduction
Breast cancer is the most common neoplastic disease in
females and is a major cause of death in women. In 2014, it
was estimated that approximately 295.24 women and 2.36
men in the United States were newly diagnosed with
breast cancer and about 40 cases died each year [1]. Female
breast cancer is also reported with the highest frequency in
Vietnam.article under the CC BY-NC-ND license (http://
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breast mutagenesis and breast carcinogenesis seem to be linked
to reactive oxygen species (ROS) [2]. Especially, free radicals are
important factor in initiation and progression of tumor [3].
However, organisms have ability to prevent free radical-
induced damages with their own antioxidant enzyme system.
Also, the antioxidant enzymes such as superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx) can
reduce different stages of carcinogenesis [4]. The 7,12-
dimethylbenz(a)anthracene (DMBA), a potent carcinogen, has
been widely used in model of mammary tumorigenesis [5]. This
molecular disrupts the balance of prooxidant-antioxidant, lead-
ing to lipid peroxidation process, which is indicated and asso-
ciated with various cancer diseases, including breast cancer [6].
Panax notoginseng (Burk.) F. H. Chen (P. notoginseng)
(Araliaceae) is a medicinal plant found in some Asian countries,
including Vietnam. P. notoginseng has many beneﬁcial effects
on the immune system and cardiovascular system. Moreover, its
haemostatic, hypolipidemic, hepatoprotective, renoprotective,
antioxidant, anti-inﬂammatory, anti-tumor and estrogen-like
activities have been reported [7,8]. It is well known that
saponins are mainly active compounds of P. notoginseng.
Most of them belong to 20(S)-protopanaxadiol and 20(S)-
protopanaxatriol structure. Ginsenosides Rg1, Rb1, Rd and
notoginsenoside R1 are responsible for the plant's
pharmacological activities and are major saponin components
in P. notoginseng roots [8]. However, saponin has poor
intestinal absorption due to their unfavorable physicochemical
properties including the large molecular mass, high molecular
ﬂexibility, high hydrogen-bonding capacity and poor mem-
brane permeability. Additionally, rapid and extensive biliary
excretion is another factor limiting the oral bioavailability of
saponins [9]. Different novel delivery systems have been used to
improve the membrane permeability and subsequently increase
the compound bioavailability. Of those, natural product–
phospholipids complex technology has been effectively
increased the absorption of medicinal plant extract via oral
administration [10]. The natural product–phospholipids
complex structures contain the natural active compound bound
to phospholipids, such as phosphatidylcholine and
phosphatidylethanolamine. Therefore, natural product–
phospholipids complex is a lipid compatible molecular
complex [11]. In the present study, we extracted saponin from
P. notoginseng roots and prepared the phospholipid complex
of this saponin extract. Its cytotoxic effects against human
lung cancer NCI-H460 and breast cancer cell lines BT474
were evaluated. We also investigated the in vivo antitumor ac-
tivity on DMBA-induced breast cancer rat model by evaluating
body weight, tumor volume, lipid peroxidation status and anti-
oxidant enzyme activities.
2. Materials and methods
2.1. Chemicals and reagents
DMBA, paclitaxel, MTS and phenazine methosulfate were
purchased from Sigma–Aldrich, Singapore. Phospholipid, Tris–
HCl, MgCl2, ethylene glycol tetraacetic acid, ethylene diamine
tetra-acetic acid, leupeptin, pepstatin, phenylmethylsulfonyl
ﬂuoride, 1-methyl-2-phenylindole, butylated hydroxytoluene,
1,1,3,3-tetramethoxypropane, pyrogallol, hydro peroxide and
dimethyl sulfoxide (DMSO) were obtained from Merck,Germany. Ethanol, ether, n-butanol and the other reagents were
of analytical grade.2.2. Preparation of saponin extract from P. notoginseng
The roots of P. notoginseng in Lao Cai Province, North
Vietnam were collected in October 2014. Then, these samples
were further classiﬁed and identiﬁed by Professor Hai Nguyen
Thanh (School of Medicine and Pharmacy, Vietnam National
University, Hanoi). A voucher specimen was deposited at the
herbarium of School of Medicine and Pharmacy, Vietnam Na-
tional University.
Total P. notoginseng saponins were prepared by a method
described previously [12]. The P. notoginseng roots were
extracted with 80% ethanol (9 L × 3 times) at room
temperature for a week. After ﬁltration, the combined ethanol
extract was then concentrated to yield a dry residue (840 g).
This crude extract was then suspended in H2O (2 L),
partitioned successively with ether (3 × 1.5 L) and n-BuOH
(3 × 1.5 L), and ﬁnally suspended concentrated and dried in
vacuum (60 C) to yield a dry residue (155 g). The dried
extract was then applied to D101 macroporous resin column
chromatography, washed with water and eluted with ethanol to
obtain total P. notoginseng saponins extract.2.3. Preparation of saponin–phospholipid complex
Saponin–phospholipid complex was prepared by mixing
P. notoginseng saponin extract with phospholipid at a molar
ratio of 1:3. The amount of standardized extract of
P. notoginseng and phospholipid were weighed and taken in a
250-mL round bottom ﬂask, and then 40 mL of dichloromethane
was added. The mixture was reﬂuxed at 40 C for 2 h. The
resultant clear solution was evaporated and 50 mL of n-hexane
was added with continuous stirring. The saponin extract–phos-
pholipid complex was precipitated and the precipitate was
ﬁltered and dried under vacuum to remove the traces of solvents.
The resultant saponin extract–phospholipid complex (yield 92%,
w/w) was kept in an amber colored glass bottle, ﬂushed with
nitrogen and stored at room temperature.2.4. Cytotoxicity assay
The cytotoxic effects of saponin extract and saponin–phos-
pholipid complex on the human lung cancer cell NCI-H460 and
human breast cancer cell BT474 were investigated by using the
MTS assay. Cells (5000 cells/well) were seeded into 96-well
plates and incubated at 37 C under 5% CO2 and 95% air
overnight to allow attachment onto the wells. All samples
(saponin extract, saponin–phospholipid complex, and paclitaxel
as positive control) were diluted in DMSO. Saponin extract and
saponin–phospholipid complex were added to the wells at ﬁnal
concentration range of 0.25–1000 mg/mL whereas paclitaxel
was used at a concentration range of 0.039–5 mg/mL. The
maximum concentration of DMSO in culture media was
adjusted to 1% (v/v). After incubation at 37 C in an atmosphere
of 5% CO2 and 95% air for 72 h, 20 mL of MTS was added to
each well and after 2–4 h incubation, the absorbance at 490 nm
was measured using a 96-well microplate reader. All experi-
ments were performed in triplicate. The percentage of cell
viability was calculated using the formula:
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The IC50 for cell growth was calculated from the equations of
the dose–response curves.
2.5. Animals
A total of 65 female Sprague–Dawley rats (45-day old, 180–
210 g) were purchased from Charly-River Company (USA). All
experimental procedures were reviewed and approved by the
Ethical Committee of the Vietnam National University, Hanoi.
Procedures were performed according to the guidelines of School
ofMedicine and Pharmacy,VietnamNationalUniversity,Hanoi on
the ethical use of animals. Rats were maintained in standard con-
ditions [a good ventilation room, (28.0 ± 0.5) C, (55 ± 5)% relative
humidity and 12 h light/dark cycles]. Rats were housed in cage and
given with a standard (Zeigler, USA) diet ad libitum before use.
2.6. DMBA treatment
After 5 days of acclimatization, rats were randomly divided
into seven tested groups of 10 animals and one control group of
5 animals. Treated rats were injected subcutaneously into the
mammary gland with a DMBA dose of 25 mg/kg body weight
with interval 1 week for 30 days. Rats were palpated weekly to
check for tumor appearance and tumor size. The treatment of
each group was as follow: the rats in Group I (normal control)
were fed with normal diet; the rats in Group II (DMBA) were fed
with normal diet without any treatment; the rats in Group III
(paclitaxel) were given paclitaxel (33 mg/kg body weight)
intragastrically by gavaging for 30 days; the rats in Group IV
(Sap 50) were given saponin extract (50 mg/kg body weight)
intragastrically by gavaging for 30 days; the rats in Group V
(Sap 150) were given saponin extract (150 mg/kg body weight)
intragastrically by gavaging for 30 days; the rats in Group VI
(Phyt 150) were given saponin–phospholipid complex (150 mg/
kg body weight) intragastrically by gavaging for 30 days (the
amount of saponin in Phyt 150 saponin–phospholipid complex
was 50 mg) and the rats in Group VII (Phyt 450) were given
saponin–phospholipid complex (450 mg/kg body weight)
intragastrically by gavaging for 30 days (the amount of saponin
in Phyt 150 saponin–phospholipid complex was 150 mg).
All rats were weighted daily. All changes in tumor volume
and body weight were recorded. Tumor volume was calculated
using the formula:
V = 0.5 × D × R2where, V is tumor volume (mm3), D is tumor length (mm) and R
is tumor width (mm).
Tumor inhibition was calculated at the ﬁnal day of experi-
mental using the formula:
Inhibition (%) = (A − B)/A × 100where, A is tumor size of DMBA group and B is tumor size of
treated group.
On Day 30, rats in all groups were sacriﬁced by cervical
dislocation. All breast tissues were resected, washed in 0.9%NaCl
and frozen rapidly at −80 C. Frozen tissues were defrosted,
weighted and homogenized in ice-cold lysis buffer, containing50 mmol/L Tris–HCl (pH 7.5), 8 mmol/L MgCl2, 5 mmol/L
ethylene glycol tetraacetic acid, 0.5 mmol/L ethylene diamine
tetraacetic acid, 0.01 mg/mL leupeptin, 0.01 mg/mL pepstatin,
0.01 mg/mL aprotinin, 1 mmol/L phenylmethylsulfonyl ﬂuoride
and 250 mmol/L NaCl. Homogenates were then centrifuged at
10020 r/min at 4 C. The supernatants were collected and stored
until use at −80 C. Protein concentration was determined by
Noble and Bailey's method [13].
2.7. Lipid peroxidation assay
Lipid peroxidation assay was performed by determining the
reaction of malonaldehyde with two molecules of 1-methyl-2-
phenylindole at 45 C as described previously [14]. The
reaction mixture consisted of 0.64 mL of 10.3 mmol/L 1-
methyl-2-phenylindole, 0.2 mL of sample and 10 mL of 2 mg/
mL butylated hydroxytoluene. After vigorously mixing,
0.15 mL of 37% v/v HCl was added. The mixture was incubated
at 45 C for 45 min and centrifuged at 9147 r/min. Cleared
supernatant absorbance was recorded at 586 nm. A calibration
curve prepared from 1,1,3,3-tetramethoxypropane (Sigma–
Aldrich, Singapore) was used for calculation. Peroxidized lipids
were expressed as nmol malondialdehyde (MDA) equivalents/
mg of protein.
2.8. SOD activity determination
SOD activity was determined as described previously [14].
This method is based on the capacity of SOD to inhibit the
autoxidation of pyrogallol. Each assay was measured in
triplicate.
2.9. CAT activity determination
CAT activity was measured in triplicate by monitoring the
disappearance of H2O2 at 240 nm as described previously [14].
Each assay was measured in triplicate.
2.10. GPx activity determination
GPx activity was measured with a coupled enzyme assay as
described previously [14]. Each assay was measured in triplicate.
2.11. Statistical analysis
All data are expressed as mean ± SD. One-way ANOVA was
used to determine signiﬁcance among groups. Statistical sig-
niﬁcance was set at P < 0.05.3. Results
3.1. Cytotoxicity test
The in vitro cytotoxicity of saponin extract, saponin–phos-
pholipid complex and paclitaxel against two cancer cell lines
was evaluated by MTS assay. The results were shown in
Table 1. Saponin extract showed mild cytotoxicity against NCI-
H460 and cancer cell lines BT474 with IC50 values of 47.97 and
86.24 mg/mL, respectively. Saponin–phospholipid complex
showed stronger cytotoxicity compared to saponin extract
against the NCI-H460 and cancer cell lines BT474 with IC50
Table 1
The cytotoxicity of saponin extract, saponin–phospholipid complex and
paclitaxel on human lung cancer (NCI-H460) and breast cancer cell lines
(BT474) (mg/mL).
Treatments IC50
Human lung cancer cell
line NCI-H460
Human breast
cancer cell line
BT474
Saponin extract 47.97 ± 1.03 86.24 ± 1.45
Saponin–phospholipids
complex
28.47 ± 0.67 53.18 ± 1.14
Paclitaxel 0.51 ± 0.09 0.52 ± 0.07
Data were showed as mean ± SD of IC50 of three independent
experiments.
Table 3
The effect of saponin extract, saponin–phospholipid complex and
paclitaxel on lipid peroxidation and antioxidant enzymes in rat breast
tissue.
Treatment
groups
MDA
(nmol/mg
protein)
SOD
(IU/min/mg
protein)
CAT
(IU/min/mg
protein)
GPx
(IU/min/mg
protein)
Normal
control
0.45 ± 0.13 6.10 ± 0.70 86.45 ± 3.36 6.41 ± 0.30
DMBA 1.95 ± 0.12* 1.50 ± 0.40* 27.26 ± 2.14* 2.14 ± 0.09*
Paclitaxel 0.93 ± 0.11# 3.60 ± 0.70# 55.34 ± 3.58# 4.57 ± 0.12#
Sap 50 1.75 ± 0.21 2.20 ± 0.30 32.12 ± 2.19 2.89 ± 0.23
Sap 150 1.38 ± 0.14# 2.80 ± 0.20# 40.12 ± 3.51# 3.33 ± 0.15#
Phyt 150 1.45 ± 0.18# 2.60 ± 0.40 36.14 ± 2.76 3.15 ± 0.21
Phyt 450 1.24 ± 0.16# 3.00 ± 0.60# 45.26 ± 3.54# 4.16 ± 0.17#
Values were expressed as mean ± SD. *: Signiﬁcant difference compared
with the control group, P < 0.05 (n = 10); #: Signiﬁcant difference
compared with the DMBA group, P < 0.05.
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cytotoxicity could be explained by saponin–phospholipid com-
plex which had more lipophilic property than saponin extract.
Then, it could have easily gone through the membrane cell to
provide more potent cytotoxicity for cancer cells.
3.2. Anti-tumor activity
Table 2 shows the body weight and tumor volume of rats in
each group. Comparing to control group, there was a signiﬁcant
decrease in the body weight of rats in DMBA group (P < 0.05).
Rats in paclitaxel and Phyt 450 treated-groups showed signiﬁcant
increase in their body weight (P < 0.05) when compared with
DMBA group. Sap 50, Sap 150 and Phyt 150 treated-groups
tended to have higher body weight than DMBA group, but not
statistically signiﬁcant. The tumor volume of rats in DMBA
group was signiﬁcantly less than the group treated with pacli-
taxel, Sap 150, Phyt 150 and Phyt 450 (P < 0.05). However, rats
in Sap 50 group tended to have lower tumor volume than those in
DMBA group. Paclitaxel reduced tumor volume more than 50%,
which was higher than any other compounds used in this study.
Comparison between Sap 50 and Phyt 150, which both contained
about 50 mg saponin compounds, Phyt 150 had two fold higher
in percentage of tumor reduction. For Sap 150 and Phyt 450,
which both contained about 150 mg saponin compounds, slightly
reduction of tumor volume (%) was observed.
3.3. Lipid peroxidation
The levels of lipid peroxidation product (MDA) from the rat
breast tissues in the studied groups were shown in Table 3. ATable 2
The effect of saponin extract, saponin–phospholipid complex and
paclitaxel on the body weight and tumor volume of rats.
Treatment
groups
Body
weight (g)
Tumor volume
(mm3)
Reduction of
tumor (%)
Normal control 243.5 ± 15.4 – –
DMBA 168.5 ± 13.6* 41.5 ± 2.8
Paclitaxel 225.7 ± 14.3# 19.4 ± 1.9# 53.25
Sap 50 189.4 ± 14.1 37.3 ± 2.1 10.12
Sap 150 205.3 ± 10.7 31.5 ± 3.4# 24.09
Phyt 150 195.9 ± 15.2 33.4 ± 2.7# 19.52
Phyt 450 210.4 ± 9.5# 27.6 ± 2.5# 28.67
Values were expressed as mean ± SD. *: Signiﬁcant difference compared
with the control group, P < 0.05 (n = 10); #: Signiﬁcant difference
compared with the DMBA group, P < 0.05.signiﬁcant increase in MDA level was observed in the DMBA
group when compared with control group (P < 0.05). A sig-
niﬁcant decrease in MDA levels was observed in group of
paclitaxel, Sap 150, Phyt 150 and Phyt 450 (P < 0.05). MDA
level in rats of Sap 50 group tended to decrease but it was not
signiﬁcantly different.
3.4. Biochemical analysis
Activities of several antioxidant enzymes including CAT,
SOD and GPx in the breast tissue of control and experimental
animals were reported in Table 3. Rats in DMBA group showed
a signiﬁcant lower in the activities of these antioxidants
compared with control group (P < 0.05). Groups treated with
paclitaxel, Sap 150 and Phyt 450 showed signiﬁcant higher
levels of CAT, SOD and GPx compared with DMBA group
(P < 0.05). These enzyme activities tended to increase in Sap 50
and Phyt 150 groups compared with DMBA group.
4. Discussion
Recent studies have reported the cytotoxicity and anti-tumor
activity of saponins extracted from P. notoginseng. The mech-
anism action may relate to the accumulation of cells in G1 or S
phase of cell cycle and apoptosis [15]. In this study, we showed
that saponin extract has mild cytotoxicity and saponin–
phospholipid complex had strong cytotoxicity towards the
NCI-H460 and cancer cell lines BT474 (Table 1). Our data
were supported by the study of Park et al. [16]. They showed that
the water extract of P. notoginseng inhibited the growth and
induced apoptosis in A549 and in NCI-H460 human lung car-
cinoma cells. The proposed mechanism of P. notoginseng may
involve in up-regulation of pro-apoptotic Bax, down-regulation
of anti-apoptotic Bcl-2 expression, loss of mitochondrial mem-
brane potential, activation of proteolytic of caspases and
dephosphorylation of the Akt signaling pathway [17]. In this
study, we showed that saponin–phospholipid complex had
stronger cytotoxicity than saponin extract. This result may be
explained due to saponin–phospholipid complex is more
compatibility to lipid than saponin extract. Therefore, it can be
able to transport from a hydrophilic environment into the
hydrophobic environment of the enterocyte cell membrane and
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P. notoginseng extract possesses signiﬁcant antiproliferative
activities in human breast carcinoma MCF-7 cell lines [19].
They also identiﬁed that ginsenoside Rb1 is the responsible
chemical constituent of antiproliferation effects on the MCF-
7 cells [19].
The present investigation reveals that saponin extract and
saponin–phospholipid complex exhibited potential anticancer
activity on DMBA-induced mammary tumors in rats (Table 2).
Our results showed that in all the treated groups, the body
weight was slightly increased and the tumor volume was
decreased compared with DMBA group (Table 2). Moreover,
the percentage of tumor reduction in these groups was statisti-
cally signiﬁcant compared with DMBA-group (P < 0.05). Our
data are agreed with previous study of Park et al. who showed
that water extract of P. notoginseng had potential capacity to
inhibit the growth of solid tumors induced by NCI-H460 in mice
[16]. They reported that the tumor weight and volume had
decreased and the mean survival time of mice was also
increased [16].
DMBA is a carcinogen which can produce free radical and
generate oxidative stress to produce deleterious effects by
starting lipid peroxidation [20]. It has been used to induce the
mammary carcinogenesis in animals in many studies [20,21]. In
our study, the administration of DMBA in rats was
accompanied by signiﬁcant increase in lipid peroxidation and
decrease in the activities of antioxidant enzymes. Our results
were similar to several previous studies. Selamoglu has shown
that DMBA induced signiﬁcant decrease in the levels of GPx,
CAT, glutathione reductase activities of erythrocyte and total
glutathione level and increase in MDA levels in adult female
Wistar rats [22]. Padmavathi et al. also showed an increase in
the extent of lipid peroxidation and a decrease in the activities
of SOD, CAT, GPx and non-enzymic antioxidants (reduced
glutathione, vitamin C and vitamin E) levels on DMBA-induced
mammary carcinogenesis in rats [23].
It is well known that O2
−, H2O2 and OH play an important
role in carcinogenesis. SOD, CAT and GPx are principally
antioxidant enzymes, scavenging free radical, preventing lipid
peroxidation and protecting cellular and molecular against ROS
damages [2]. The biochemical function of SOD is to convert O2
−
to O2 and H2O2. Then H2O2 is further converted to water and O2
by CAT. GPx reduces lipid hydroperoxides to their
corresponding alcohols and reduces free H2O2 to water.
Previous study has shown that the antioxidant defense system
was altered in cancerous breast tissues [2]. Our study has
demonstrated that saponin extract from P. notoginseng and
saponin–phospholipid complex could increase the CAT's,
SOD's, GPx's activities and at the same time decrease the level
of lipid peroxidation. In the present study, antioxidant enzyme
activities of CAT, SOD and GPx were signiﬁcantly high in
Phyt 450 and Sap 150 treated-groups compared with the
DMBA group. Our data agreed with the study of Han et al. [24].
They revealed that the extracts of P. notoginseng could reduce
the oxidative stress on anti-myocardial ischemia injuries
in vivo by decreasing MDA level and elevating the activities of
SOD and GPx [24]. Ginsenoside Rd, one of the main compounds
in P. notoginseng saponins, has a potential neuroprotective agent
for cerebral ischemic injury by increasing L-glutathione content
and improving antioxidant activity of CAT, SOD and GPx in
hippocampal neurons [25]. Ginsenoside Rd also reduced the
intracellular ROS level, decreased MDA level and enhancedthe activities of SOD and GPx on H2O2-induced cytotoxicity
PC12 cell line [26]. In the present study, Sap 50 and Phyt 150
(each contained 50 mg saponin) treated-groups showed
slightly increase in the activities of SOD, CAT and GPx, but
they are not signiﬁcantly different. However, when the doses of
saponin extract and saponin–phospholipid complex were
increased to 150 mg/kg body weight and 450 mg/kg body
weight, respectively (Sap 150 group and Phyt 450 group con-
tained 150 mg saponin each), strong differences in these anti-
oxidant activities were found. Our ﬁndings indicated that the
same amount of saponin content and saponin–phospholipid
complex had stronger antioxidant enzyme activities than saponin
extract.
In conclusion, the present study reveals that saponin extrac-
ted from the roots of P. notoginseng has anti-tumor activity on
human lung cancer (NCI-H460) and human breast cancer cell
lines (BT474). Our data suggest that the administration of
saponin extract at a dose of 150 mg/kg body weight or saponin–
phospholipid complex at 450 mg/kg body weight (each of them
contained 150 mg saponin) signiﬁcantly decreases the tumor
progression on DMBA-induced breast cancer rats and increases
the levels of antioxidant enzymes including SOD, CAT and
GPx. Our results showed that saponin–phospholipids complex
has potential to be used as a delivery system for saponin
extracted from the roots of P. notoginseng. Development of
natural product–phospholipids complex as a delivery system of
medicinal plant extracts should be further studied in pharma-
ceutical industry.Conﬂict of interest statement
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